Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD(®) and VANTAFLU(®) in South Korean Subjects Aged ≥65 Years

Por Yoo, Byung Wook, Kim, Chang Oh, Izu, Allen, Arora, Ashwani Kumar, Heijnen, Esther
Publicado no Infect Chemother (2018)

Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity

Por Norman, Robert J., Zegers-Hochschild, Fernando, Salle, Bruno S., Elbers, Jolanda, Heijnen, Esther, Marintcheva-Petrova, Maya, Mannaerts, Bernadette
Publicado em 2011

987. Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV): A Randomized, Observer Blind, Multicenter Study

Por Daly, Wendy, Ramsey, Keith, Forsten, Aino, Heijnen, Esther, Leav, Brett, Oberye, Janine, Zhang, Bin, Pacciarini, Filippo, Vesikari, Timo
Publicado no Open Forum Infect Dis (2018)

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomize...

Por Esposito, Susanna, Fling, John, Chokephaibulkit, Kulkanya, de Bruijn, Marianne, Oberye, Janine, Zhang, Bin, Vossen, Jeanique, Heijnen, Esther, Smolenov, Igor
Publicado no Pediatr Infect Dis J (2020)

Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents

Por Saez-Llorens, Xavier, Aguilera Vaca, Diana Catalina, Abarca, Katia, Maho, Emmanuelle, Graña, Maria Gabriela, Heijnen, Esther, Smolenov, Igor, Dull, Peter M
Publicado no Hum Vaccin Immunother (2015)

MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial...

Por Cruz-Valdez, Aurelio, Valdez-Zapata, Gabriel, Patel, Sanjay S., Castelli, Flavia V., Garcia, Marcia G., Jansen, Wim T., Arora, Ashwani Kumar, Heijnen, Esther
Publicado no Hum Vaccin Immunother (2018)

902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Hea...

Por DeVincenzo, John, Gymnopoulou, Efi, De Paepe, Els, Murray, Bryan, Rosemary Bastian, Arangassery, Haazen, Wouter, Noulin, Nicolas, Comeaux, Christy, Heijnen, Esther, Eze, Kinglsey, Gilbert, Anthony, Lambkin-Williams, Rob, Schuitemaker, Hanneke, Callendret, Benoit, Sadoff, Jerald
Publicado no Open Forum Infect Dis (2019)

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment()

Por Custers, Jerome, Kim, Denny, Leyssen, Maarten, Gurwith, Marc, Tomaka, Frank, Robertson, James, Heijnen, Esther, Condit, Richard, Shukarev, Georgi, Heerwegh, Dirk, van Heesbeen, Roy, Schuitemaker, Hanneke, Douoguih, Macaya, Evans, Eric, Smith, Emily R., Chen, Robert T.
Publicado no Vaccine (2021)